| __timestamp | Ascendis Pharma A/S | Bausch Health Companies Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6274000 | 2026300000 |
| Thursday, January 1, 2015 | 9415000 | 2682700000 |
| Friday, January 1, 2016 | 11504000 | 2810000000 |
| Sunday, January 1, 2017 | 13482000 | 2582000000 |
| Monday, January 1, 2018 | 25057000 | 2473000000 |
| Tuesday, January 1, 2019 | 48473000 | 2554000000 |
| Wednesday, January 1, 2020 | 76669000 | 2367000000 |
| Friday, January 1, 2021 | 160180000 | 2624000000 |
| Saturday, January 1, 2022 | 221227000 | 2625000000 |
| Sunday, January 1, 2023 | 264410000 | 2917000000 |
| Monday, January 1, 2024 | 284545000 |
Cracking the code
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Ascendis Pharma A/S and Bausch Health Companies Inc. have taken different paths in this regard over the past decade. From 2014 to 2023, Ascendis Pharma A/S saw a significant increase in SG&A expenses, growing from approximately $6.3 million to $264 million, marking a staggering 4,100% rise. In contrast, Bausch Health Companies Inc. maintained a more stable trajectory, with expenses fluctuating around the $2.5 billion mark, peaking at $2.9 billion in 2023. This stability suggests a more controlled approach to managing operational costs. While Ascendis Pharma's rapid growth in expenses might indicate aggressive expansion, Bausch Health's steadiness could reflect a mature, cost-efficient strategy. Understanding these trends offers valuable insights into each company's operational priorities and financial health.
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or Bausch Health Companies Inc.
Comparing SG&A Expenses: Johnson & Johnson vs Bausch Health Companies Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Ascendis Pharma A/S
Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Amneal Pharmaceuticals, Inc.
Comparing SG&A Expenses: Ascendis Pharma A/S vs Xencor, Inc. Trends and Insights
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs Bausch Health Companies Inc.
Blueprint Medicines Corporation and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Madrigal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Corcept Therapeutics Incorporated vs Bausch Health Companies Inc.: SG&A Expense Trends
Alpine Immune Sciences, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Bausch Health Companies Inc. vs ImmunityBio, Inc.
Comparing SG&A Expenses: Bausch Health Companies Inc. vs Arrowhead Pharmaceuticals, Inc. Trends and Insights